Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gleave

Showing results (121-130 of 259) with videos related to

Pageof 26
Sort By:
Plos One|February 25, 2017
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapyMichael L Blute, Nathan Damaschke, Jennifer Wagner, et al.
Cancer Research|March 16, 2013
Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancerMasaki Shiota, Jennifer L Bishop, Ka Mun Nip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical ProstatectomyRashid K Sayyid, Andrew Evans, Karen Hersey, et al.
European Urology|October 6, 2018
Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate CancerLorenzo Tosco, Alberto Briganti, Antony Vincent D'amico, et al.
Oncogene|January 7, 2023
Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodelingNicholas Nikesitch, Eliana Beraldi, Fan Zhang, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 14, 2013
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 updateFred Saad, Sebastien Hotte, Charles Catton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancerKarim Fizazi, Karim S Fizazi, Celestia S Higano, et al.
Cancer Gene Therapy|July 14, 2023
Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancerNing Kang, Hui Xue, Yen-Yi Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancerKim N Chi, Lillian L Siu, Hal Hirte, et al.
Plos One|August 14, 2020
Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancerHolger H H Erb, Julia Bodenbender, Florian Handle, et al.
Pageof 26

Showing results (121-130 of 259) with videos related to

Sort By:
Pageof 26
Plos One|February 25, 2017
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapyMichael L Blute, Nathan Damaschke, Jennifer Wagner, et al.
Cancer Research|March 16, 2013
Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancerMasaki Shiota, Jennifer L Bishop, Ka Mun Nip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical ProstatectomyRashid K Sayyid, Andrew Evans, Karen Hersey, et al.
European Urology|October 6, 2018
Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate CancerLorenzo Tosco, Alberto Briganti, Antony Vincent D'amico, et al.
Oncogene|January 7, 2023
Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodelingNicholas Nikesitch, Eliana Beraldi, Fan Zhang, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 14, 2013
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 updateFred Saad, Sebastien Hotte, Charles Catton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancerKarim Fizazi, Karim S Fizazi, Celestia S Higano, et al.
Cancer Gene Therapy|July 14, 2023
Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancerNing Kang, Hui Xue, Yen-Yi Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancerKim N Chi, Lillian L Siu, Hal Hirte, et al.
Plos One|August 14, 2020
Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancerHolger H H Erb, Julia Bodenbender, Florian Handle, et al.
Pageof 26